Senores Pharmaceuticals shares are under pressure after the company reported its results. In the quarter that ended in September, 2026, the pharma company recorded strong number with a rise in profit, revenue and profitability.
The Ahmedabad-based pharmaceutical company’s net profit rose 22.3% year-on-year to ₹39.5 crore in the second quarter of FY27, compared with ₹32.3 crore in the corresponding period last year.
Revenue increased 24.7% to ₹192 crore in Q2 FY27 from ₹154 crore a year earlier.
Operating performance improved during the September quarter, with Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) rising by 39% year-on-year to ₹57 crore.
In the previous cycle, the EBITDA stood at ₹41 crore.
Furthemore, the EBITDA margin expanded to 30% in Q2 from 26.9% in the corresponding quarter last year, indicating an improvement of 310 basis points.
The shares of Senores Pharmaceuticals have fallen over 6%, the stock despite slipping has made a minor recovery, while remaining in red. The shares have seen a rise of 41.63% in the past 6 months of trade.
In the past 3 months however, the shares have seen a dip of nearly 3%. The stock price now stands at ₹1,283.20.
Also Read: Tata Sons vs Tata Trusts: Why November is a crucial month for the Tata Group
Senores Pharmaceuticals shares fall 6% despite 22% rise in Q2 profit; revenue jumps 25%